The study included nearly 2 million patients, making it the largest ever conducted on this group of glucagon-like peptide-1 receptor agonists.

A study analyzing data from over 2 million veterans found that GLP-1 receptor agonists, popular weight-loss drugs like Ozempic and Wegovy, provide significant neurological and behavioral health benefits,

Demand for weight-loss medications sold under brand names such as Ozempic and Wegovy continues to surge, with a recent study reporting one in eight Americans has taken or is currently using the drugs to treat diabetes,